Eric W. Thomas

Array ( [id] => 14852185 [patent_doc_number] => 10414804 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-09-17 [patent_title] => Method of inducing an immune response by administering exosomes comprising Nef-fusion proteins [patent_app_type] => utility [patent_app_number] => 16/034237 [patent_app_country] => US [patent_app_date] => 2018-07-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 11 [patent_figures_cnt] => 25 [patent_no_of_words] => 13487 [patent_no_of_claims] => 13 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 45 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16034237 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17377066 [patent_doc_number] => 11235055 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-02-01 [patent_title] => Nucleic acids encoding mosaic conserved region HIV immunogenic polypeptides [patent_app_type] => utility [patent_app_number] => 16/023871 [patent_app_country] => US [patent_app_date] => 2018-06-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 8 [patent_figures_cnt] => 8 [patent_no_of_words] => 12497 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 56 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16023871 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16941064 [patent_doc_number] => 11053285 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-07-06 [patent_title] => Nucleic acids encoding human immunodeficiency virus type 1 (HIV-1) N-terminal deleted gp120 immunogens and methods of use [patent_app_type] => utility [patent_app_number] => 16/020543 [patent_app_country] => US [patent_app_date] => 2018-06-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 56 [patent_figures_cnt] => 44 [patent_no_of_words] => 14071 [patent_no_of_claims] => 25 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 61 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16020543 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13733237 [patent_doc_number] => 20180371086 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-12-27 [patent_title] => MULTISPECIFIC ANTIBODIES THAT TARGET HIV GP120 AND CD3 [patent_app_type] => utility [patent_app_number] => 16/014153 [patent_app_country] => US [patent_app_date] => 2018-06-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 56085 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -50 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16014153 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13733237 [patent_doc_number] => 20180371086 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-12-27 [patent_title] => MULTISPECIFIC ANTIBODIES THAT TARGET HIV GP120 AND CD3 [patent_app_type] => utility [patent_app_number] => 16/014153 [patent_app_country] => US [patent_app_date] => 2018-06-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 56085 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -50 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16014153 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13733237 [patent_doc_number] => 20180371086 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-12-27 [patent_title] => MULTISPECIFIC ANTIBODIES THAT TARGET HIV GP120 AND CD3 [patent_app_type] => utility [patent_app_number] => 16/014153 [patent_app_country] => US [patent_app_date] => 2018-06-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 56085 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -50 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16014153 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13733237 [patent_doc_number] => 20180371086 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-12-27 [patent_title] => MULTISPECIFIC ANTIBODIES THAT TARGET HIV GP120 AND CD3 [patent_app_type] => utility [patent_app_number] => 16/014153 [patent_app_country] => US [patent_app_date] => 2018-06-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 56085 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -50 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16014153 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16484305 [patent_doc_number] => 20200377906 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-12-03 [patent_title] => CODON-OPTIMIZED HUMAN NPC1 GENES FOR THE TREATMENT OF NIEMANN-PICK TYPE C1 DEFICIENCY AND RELATED CONDITIONS [patent_app_type] => utility [patent_app_number] => 16/623863 [patent_app_country] => US [patent_app_date] => 2018-06-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 27199 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16623863 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13586579 [patent_doc_number] => 20180344838 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-12-06 [patent_title] => DENV RNA VACCINES [patent_app_type] => utility [patent_app_number] => 16/009848 [patent_app_country] => US [patent_app_date] => 2018-06-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 70928 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -27 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16009848 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14762097 [patent_doc_number] => 10392433 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-08-27 [patent_title] => Broadly neutralizing antibody directed against HIV-1 GP140 [patent_app_type] => utility [patent_app_number] => 16/006420 [patent_app_country] => US [patent_app_date] => 2018-06-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 27 [patent_figures_cnt] => 27 [patent_no_of_words] => 30267 [patent_no_of_claims] => 12 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 63 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16006420 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18869836 [patent_doc_number] => 11857616 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-01-02 [patent_title] => Recombinant measles virus expressing zika virus prM and E proteins [patent_app_type] => utility [patent_app_number] => 16/618823 [patent_app_country] => US [patent_app_date] => 2018-06-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 17 [patent_figures_cnt] => 22 [patent_no_of_words] => 13843 [patent_no_of_claims] => 24 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 278 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16618823 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17073785 [patent_doc_number] => 11110164 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-09-07 [patent_title] => Lysosomal targeting of antigens employing nucleic acids encoding lysosomal membrane polypeptide/antigen chimeras [patent_app_type] => utility [patent_app_number] => 15/976453 [patent_app_country] => US [patent_app_date] => 2018-05-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 13 [patent_figures_cnt] => 26 [patent_no_of_words] => 27848 [patent_no_of_claims] => 14 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 63 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15976453 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16915855 [patent_doc_number] => 20210188947 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-06-24 [patent_title] => OPTIMIZED NUCLEIC ACID ANTIBODY CONSTRUCTS [patent_app_type] => utility [patent_app_number] => 16/611943 [patent_app_country] => US [patent_app_date] => 2018-05-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 53313 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16611943 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15931117 [patent_doc_number] => 20200157192 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-05-21 [patent_title] => FC-FUSION PROTEIN DERIVATIVES WITH HIGH DUAL HIV ANTIVIRAL AND IMMUNOMODULATORY ACTIVITY [patent_app_type] => utility [patent_app_number] => 16/612727 [patent_app_country] => US [patent_app_date] => 2018-05-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 23049 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -22 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16612727 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13957891 [patent_doc_number] => 20190055289 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-02-21 [patent_title] => IMMUNOGENS FOR HIV VACCINATION [patent_app_type] => utility [patent_app_number] => 15/970216 [patent_app_country] => US [patent_app_date] => 2018-05-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 15629 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -35 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15970216 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16778394 [patent_doc_number] => 20210115472 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-04-22 [patent_title] => Self-Inactivating Viral Vector [patent_app_type] => utility [patent_app_number] => 16/607980 [patent_app_country] => US [patent_app_date] => 2018-05-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 21958 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -53 [patent_words_short_claim] => 23 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16607980 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16157371 [patent_doc_number] => 20200216918 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-07-09 [patent_title] => FLUORESCENT ENVELOPED VIRAL PARTICLES AS STANDARDS FOR NANOSALE FLOW CYTOMETRY [patent_app_type] => utility [patent_app_number] => 16/650895 [patent_app_country] => US [patent_app_date] => 2018-04-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 20526 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -64 [patent_words_short_claim] => 23 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16650895 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16791762 [patent_doc_number] => 20210121579 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-04-29 [patent_title] => GENE THERAPY [patent_app_type] => utility [patent_app_number] => 16/606633 [patent_app_country] => US [patent_app_date] => 2018-04-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 20305 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 13 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16606633 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15436079 [patent_doc_number] => 20200032223 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-01-30 [patent_title] => METHOD FOR PRODUCING RECOMBINANT VIRUS [patent_app_type] => utility [patent_app_number] => 16/604194 [patent_app_country] => US [patent_app_date] => 2018-04-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11414 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -72 [patent_words_short_claim] => 54 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16604194 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15895361 [patent_doc_number] => 20200147199 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-05-14 [patent_title] => COMPOSITIONS AND METHODS RELATED TO HUMAN NEUTRALIZING ANTIBODIES TO ZIKA AND DENGUE 1 VIRUS [patent_app_type] => utility [patent_app_number] => 16/603341 [patent_app_country] => US [patent_app_date] => 2018-04-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 36012 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -28 [patent_words_short_claim] => 37 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16603341 [rel_patent_id] =>[rel_patent_doc_number] =>)